Last updated: 2026 Semaglutide is a GLP-1 mono-agonist
Lipohypertrophy not only causes cosmetic changes but can impair drug absorption, leading to unpredictable medication levels and reduced therapeutic effect
However, research suggests semaglutide may have direct effects on lipid metabolism independent of weight loss alone
People who are leaner sometimes struggle with abdominal injections because the fat layer there can be thin, increasing the risk of accidental intramuscular injection
June 1, 2026: Over 100 Lawsuits in the GLP-1 NAION MDL, Ozempic Patient Sues After Becoming Blind from NAION The GLP-1 NAION multidistrict litigation now has 110 lawsuits in it, as of June 1, 2026
Add The New York Post on Google Its the miracle drug that promises to shrink your size except where it matters